Fulcrum Enterprise Value vs Free Cash Flow Analysis

FULC Stock

USD 7.06 0.09 1.26%

Fulcrum Therapeutics financial indicator trend analysis is much more than just examining Fulcrum Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fulcrum Therapeutics is a good investment. Please check the relationship between Fulcrum Therapeutics Enterprise Value and its Free Cash Flow accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.

Enterprise Value vs Free Cash Flow

Enterprise Value vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fulcrum Therapeutics Enterprise Value account and Free Cash Flow. At this time, the significance of the direction appears to have no relationship.

The correlation between Fulcrum Therapeutics' Enterprise Value and Free Cash Flow is 0.0. Overlapping area represents the amount of variation of Enterprise Value that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Fulcrum Therapeutics, assuming nothing else is changed. The correlation between historical values of Fulcrum Therapeutics' Enterprise Value and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Enterprise Value of Fulcrum Therapeutics are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Enterprise Value i.e., Fulcrum Therapeutics' Enterprise Value and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

0.0

Relationship Direction	Flat
Relationship Strength	Insignificant

View All Relationships

Enterprise Value

Enterprise Value (or EV) is usually referred to as Fulcrum Therapeutics theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Fulcrum Therapeutics debt, but would also pocket its cash. Enterprise Value is more accurate representation of Fulcrum Therapeutics value than its market capitalization because it takes into account all of Fulcrum Therapeutics existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from Fulcrum Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fulcrum Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 15.60, whereas Selling General Administrative is forecasted to decline to about 25.3 M.

	2018	2019	2023	2024 (projected)
Interest Income	518K	1.5M	1.7M	1.8M
Net Interest Income	518K	1.5M	1.7M	1.8M

Interest Income Net Interest Income

Fulcrum Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.69	0.81	1.0	0.26	0.93	0.27	-0.42	-0.93	0.81	0.54	0.87	-0.03	0.9	1.0	0.81	0.95	0.92	0.83	0.93	-0.52	0.89	0.99	0.87	1.0	0.7
Other Current Liab	0.69		0.71	0.66	0.23	0.71	0.39	-0.32	-0.76	0.52	0.45	0.85	-0.17	0.78	0.68	0.36	0.74	0.71	0.84	0.74	-0.47	0.51	0.76	0.8	0.67	0.57
Total Current Liabilities	0.81	0.71		0.78	0.5	0.81	0.27	-0.51	-0.74	0.93	0.59	0.84	-0.05	0.72	0.81	0.85	0.77	0.66	0.76	0.78	-0.7	0.58	0.78	0.97	0.8	0.49
Total Stockholder Equity	1.0	0.66	0.78		0.22	0.93	0.24	-0.38	-0.92	0.79	0.51	0.85	-0.01	0.9	1.0	0.81	0.94	0.93	0.8	0.93	-0.5	0.91	0.99	0.83	1.0	0.71
Other Liab	0.26	0.23	0.5	0.22		0.14	0.74	-0.95	-0.04	0.28	0.88	0.39	-0.68	0.09	0.26	0.27	0.15	-0.06	0.56	0.08	0.1	-0.11	0.18	0.55	0.29	0.08
Net Tangible Assets	0.93	0.71	0.81	0.93	0.14		0.28	-0.25	-0.97	0.84	0.41	0.78	-0.05	0.92	0.94	0.78	0.96	0.87	0.76	0.99	-0.51	0.86	0.94	0.84	0.92	0.75
Property Plant And Equipment Net	0.27	0.39	0.27	0.24	0.74	0.28		-0.74	-0.19	0.09	0.75	0.32	-0.96	0.23	0.26	-0.03	0.26	0.01	0.64	0.23	0.46	0.03	0.23	0.43	0.29	0.23
Net Debt	-0.42	-0.32	-0.51	-0.38	-0.95	-0.25	-0.74		0.2	-0.29	-0.98	-0.56	0.63	-0.29	-0.41	-0.29	-0.32	-0.11	-0.71	-0.22	-0.06	-0.05	-0.33	-0.61	-0.45	-0.25
Retained Earnings	-0.93	-0.76	-0.74	-0.92	-0.04	-0.97	-0.19	0.2		-0.73	-0.38	-0.83	-0.06	-0.98	-0.92	-0.7	-0.99	-0.93	-0.77	-0.99	0.56	-0.84	-0.95	-0.8	-0.91	-0.84
Accounts Payable	0.81	0.52	0.93	0.79	0.28	0.84	0.09	-0.29	-0.73		0.37	0.68	0.1	0.65	0.81	0.91	0.74	0.67	0.59	0.78	-0.68	0.73	0.77	0.85	0.79	0.38
Cash	0.54	0.45	0.59	0.51	0.88	0.41	0.75	-0.98	-0.38	0.37		0.68	-0.59	0.47	0.53	0.35	0.49	0.26	0.82	0.4	-0.02	0.18	0.47	0.71	0.58	0.42
Non Current Assets Total	0.87	0.85	0.84	0.85	0.39	0.78	0.32	-0.56	-0.83	0.68	0.68		-0.04	0.88	0.86	0.62	0.87	0.79	0.93	0.82	-0.6	0.64	0.87	0.92	0.87	0.66
Non Currrent Assets Other	-0.03	-0.17	-0.05	-0.01	-0.68	-0.05	-0.96	0.63	-0.06	0.1	-0.59	-0.04		0.04	-0.03	0.21	0.0	0.21	-0.41	0.02	-0.66	0.15	0.0	-0.18	-0.05	-0.01
Other Assets	0.9	0.78	0.72	0.9	0.09	0.92	0.23	-0.29	-0.98	0.65	0.47	0.88	0.04		0.9	0.63	0.99	0.89	0.83	0.96	-0.55	0.77	0.92	0.8	0.9	0.88
Cash And Short Term Investments	1.0	0.68	0.81	1.0	0.26	0.94	0.26	-0.41	-0.92	0.81	0.53	0.86	-0.03	0.9		0.82	0.94	0.92	0.82	0.93	-0.52	0.9	0.99	0.86	1.0	0.7
Net Receivables	0.81	0.36	0.85	0.81	0.27	0.78	-0.03	-0.29	-0.7	0.91	0.35	0.62	0.21	0.63	0.82		0.72	0.71	0.49	0.74	-0.7	0.7	0.77	0.76	0.8	0.5
Common Stock Total Equity	0.95	0.74	0.77	0.94	0.15	0.96	0.26	-0.32	-0.99	0.74	0.49	0.87	0.0	0.99	0.94	0.72		0.9	0.83	0.99	-0.53	0.83	0.95	0.84	0.94	0.85
Common Stock Shares Outstanding	0.92	0.71	0.66	0.93	-0.06	0.87	0.01	-0.11	-0.93	0.67	0.26	0.79	0.21	0.89	0.92	0.71	0.9		0.68	0.9	-0.61	0.89	0.96	0.71	0.91	0.73
Non Current Liabilities Total	0.83	0.84	0.76	0.8	0.56	0.76	0.64	-0.71	-0.77	0.59	0.82	0.93	-0.41	0.83	0.82	0.49	0.83	0.68		0.78	-0.29	0.57	0.82	0.9	0.84	0.65
Capital Surpluse	0.93	0.74	0.78	0.93	0.08	0.99	0.23	-0.22	-0.99	0.78	0.4	0.82	0.02	0.96	0.93	0.74	0.99	0.9	0.78		-0.55	0.85	0.94	0.82	0.92	0.81
Inventory	-0.52	-0.47	-0.7	-0.5	0.1	-0.51	0.46	-0.06	0.56	-0.68	-0.02	-0.6	-0.66	-0.55	-0.52	-0.7	-0.53	-0.61	-0.29	-0.55		-0.43	-0.54	-0.58	-0.49	-0.37
Other Current Assets	0.89	0.51	0.58	0.91	-0.11	0.86	0.03	-0.05	-0.84	0.73	0.18	0.64	0.15	0.77	0.9	0.7	0.83	0.89	0.57	0.85	-0.43		0.9	0.61	0.88	0.51
Other Stockholder Equity	0.99	0.76	0.78	0.99	0.18	0.94	0.23	-0.33	-0.95	0.77	0.47	0.87	0.0	0.92	0.99	0.77	0.95	0.96	0.82	0.94	-0.54	0.9		0.84	0.98	0.72
Total Liab	0.87	0.8	0.97	0.83	0.55	0.84	0.43	-0.61	-0.8	0.85	0.71	0.92	-0.18	0.8	0.86	0.76	0.84	0.71	0.9	0.82	-0.58	0.61	0.84		0.86	0.58
Net Invested Capital	1.0	0.67	0.8	1.0	0.29	0.92	0.29	-0.45	-0.91	0.79	0.58	0.87	-0.05	0.9	1.0	0.8	0.94	0.91	0.84	0.92	-0.49	0.88	0.98	0.86		0.71
Property Plant And Equipment Gross	0.7	0.57	0.49	0.71	0.08	0.75	0.23	-0.25	-0.84	0.38	0.42	0.66	-0.01	0.88	0.7	0.5	0.85	0.73	0.65	0.81	-0.37	0.51	0.72	0.58	0.71

Click cells to compare fundamentals

Fulcrum Therapeutics Account Relationship Matchups

Fulcrum Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	110.4M	129.6M	235M	226.7M	257.7M	164.9M
Other Current Liab	5.9M	7.7M	74K	9.6M	8.7M	5.2M
Total Current Liabilities	12.1M	26.7M	19.2M	16.7M	13.7M	15.0M
Total Stockholder Equity	87.2M	95.2M	211.5M	198.9M	235.2M	142.3M
Other Liab	11.1M	7.7M	4.3M	197K	177.3K	168.4K
Net Tangible Assets	87.2M	95.2M	211.5M	198.9M	228.8M	240.2M
Property Plant And Equipment Net	87.9M	8.4M	7.4M	16.0M	12.4M	16.6M
Net Debt	(96.7M)	(57.0M)	(35.4M)	(21.7M)	(14.7M)	(15.5M)
Retained Earnings	(150.8M)	(221.6M)	(302.5M)	(412.3M)	(509.7M)	(484.2M)
Accounts Payable	2.2M	4.1M	4.8M	3.6M	2.8M	3.2M
Cash	96.7M	57.1M	35.4M	35.1M	25.6M	36.9M
Non Current Assets Total	10.4M	16.7M	9.0M	19.2M	15.5M	13.4M
Non Currrent Assets Other	(78.7M)	7.2M	542K	2.1M	2.0M	2.1M
Other Assets	1.2M	1.7M	1.6M	3.2M	3.7M	3.9M
Cash And Short Term Investments	96.7M	112.9M	218.2M	202.9M	236.2M	147.7M
Net Receivables	111K	2.7M	4.1M	1.1M	2.2M	1.7M
Common Stock Total Equity	23K	28K	41K	52K	59.8K	62.8K
Common Stock Shares Outstanding	11.0M	25.4M	35.4M	45.0M	61.3M	32.4M
Liabilities And Stockholders Equity	110.4M	129.6M	235M	226.7M	257.7M	164.9M
Non Current Liabilities Total	11.1M	7.7M	4.3M	11.0M	8.8M	7.7M
Capital Surpluse	237.9M	316.8M	514.4M	612.0M	703.8M	739.0M
Capital Lease Obligations	46K	50K	17K	13.4M	10.8M	11.4M
Inventory	3.0M	(2.8M)	(473K)	(852K)	(766.8K)	(728.5K)
Other Current Assets	284K	74K	4.2M	4.4M	3.7M	2.1M
Other Stockholder Equity	237.9M	316.8M	514.4M	612.0M	744.9M	404.7M
Total Liab	23.3M	34.4M	23.5M	27.7M	22.5M	22.7M
Net Invested Capital	87.2M	95.2M	211.5M	198.9M	235.2M	136.8M
Property Plant And Equipment Gross	9.2M	8.4M	7.4M	6.9M	25.2M	26.4M
Total Current Assets	100.1M	112.9M	226.0M	207.5M	242.2M	151.5M
Accumulated Other Comprehensive Income	(110.4M)	(2K)	(397K)	(797K)	(136K)	(142.8K)
Non Current Liabilities Other	150K	55K	3.1M	197K	226.6K	215.2K
Net Working Capital	87.9M	92.8M	206.8M	190.8M	228.5M	137.5M
Short Term Debt	50K	17K	9.6M	2.6M	2.2M	2.3M
Common Stock	23K	28K	41K	52K	62K	35.0K
Property Plant Equipment	9.2M	8.4M	7.4M	6.9M	7.9M	8.3M
Short Long Term Debt Total	50K	17K	469K	13.4M	10.8M	11.4M
Current Deferred Revenue	4.0M	14.9M	4.7M	934K	840.6K	798.6K
Capital Stock	23K	28K	41K	52K	62K	40.7K

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Fulcrum Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Fulcrum Therapeutics' short interest history, or implied volatility extrapolated from Fulcrum Therapeutics options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Fulcrum Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fulcrum Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fulcrum Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fulcrum Therapeutics Stock:

How To Invest In Fulcrum

Details

Is Fulcrum Stock a good investment?

Details

What is Fulcrum Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.

You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Fulcrum Stock analysis

When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Global Correlations Find global opportunities by holding instruments from different markets
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators

Is Fulcrum Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.59)

Revenue Per Share

0.046

Quarterly Revenue Growth

0.272

Return On Assets

(0.29)

Return On Equity

(0.45)

The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Fulcrum Enterprise Value vs Free Cash Flow Analysis

Enterprise Value vs Free Cash Flow

Enterprise Value vs Free Cash Flow Correlation Analysis

Correlation Coefficient

Enterprise Value

Free Cash Flow

Fulcrum Therapeutics fundamental ratios Correlations

Fulcrum Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Fulcrum Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Fulcrum Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Cash And Short Term Investments

Capital Surpluse	- 0.99	Retained Earnings
Common Stock Total Equity	- 0.99	Retained Earnings
Other Assets	- 0.98	Retained Earnings
Cash	- 0.98	Net Debt
Retained Earnings	- 0.97	Net Tangible Assets
Non Currrent Assets Other	- 0.96	Property Plant And Equipment Net